Third generation hormone blocker shown to reduce cancer risk and reduce fractures in post-menopausal women.

A five year study of 8556 post-menopausal women (aged 59-80) showed that women taking 0.5 mg lasofoxifene, an estrogen receptor modulator, had a reduced risk of developing breast cancer.  This dose of the drug reduced the risk of breast cancer by 79%.  The women chosen for the study also had low bone density and the  treatment also reduced the risk of fractures in this population.  Losofoxifene also showed protective effects against coronary events (i.e. heart attack) and stroke.